代谢型谷氨酸受体5在中枢神经系统疾病中的研究进展

朱恩妮; 吴超然; 廖红

doi:10.11665/j.issn.1000-5048.20210614

代谢型谷氨酸受体5在中枢神经系统疾病中的研究进展

中国药科大学新药筛选中心江苏省药效研究与评价服务中心，南京 210009

基金项目: 国家自然科学基金资助项目（No.82073831）

计量
- 文章访问数: 231
- HTML全文浏览量: 18
- PDF下载量: 737
出版历程
- 收稿日期: 2021-05-06
- 修回日期: 2021-10-25
- 刊出日期: 2021-12-24

Research progress of metabotropic glutamate receptor 5 in related central nervous system diseases

New Drug Screening Center,Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China

Funds: This study was supported by the National Natural Science Foundation of China (No.82073831)

摘要

摘要: 代谢型谷氨酸受体5（metabotropic glutamate receptor 5，mGluR5）是中枢谷氨酸能系统的重要受体之一，其广泛参与调控突触传递、突触可塑性、神经兴奋性/抑制性平衡等生理过程。多项研究发现，mGluR5参与介导不同神经和精神疾病的发生发展，因此其作为神经和精神疾病的潜在药物靶标日益受到关注。本文对mGluR5的结构、分布、正常生理功能、mGluR5在中枢神经系统疾病中的作用以及mGluR5药物研发现状进行概述，以期为中枢神经系统疾病的研究提供参考。
- 代谢型谷氨酸受体5 /
- 生理功能 /
- 中枢神经系统疾病 /
- 药物研发 /
- 进展
Abstract: As a key component of glutamatergic system, metabotropic glutamate receptor 5 (mGluR5) has been extensively involved in the regulation of physiological processes such as synaptic transmission, synaptic plasticity and synaptic excitation/inhibition balance.Over the past few decades, mGluR5 has been found to be closely related to multiple neurological and psychiatric disorders, thus it is of considerable interest as a drug target in the treatment of such disorders.This review summarizes the structure and distribution of mGluR5, its normal physiological function, its pathological roles in related central nervous system (CNS) diseases, as well as the current status of its drug development, in order to provide reference for further investigation.
- metabotropic glutamate receptor 5 /
- physiological function /
- central nervous system diseases /
- drug development /
- advances

HTML全文

参考文献(59)

[1]	. Pharmacol Ther，2014，142（3）：281-305.
[2]	Reiner A，Levitz J. Glutamatergic signaling in the central nervous system：ionotropic and metabotropic receptors in concert［J］. Neuron，2018，98（6）：1080-1098.
[3]	Niswender CM，Conn PJ. Metabotropic glutamate receptors：physiology，pharmacology，and disease［J］. Annu Rev Pharmacol Toxicol，2010，50：295-322.
[4]	Ellaithy A，Gonzalez-Maeso J，Logothetis DA，et al. Structural and biophysical mechanisms of class C G protein-coupled receptor function［J］. Trends Biochem Sci，2020，45（12）：1049-1064.
[5]	Sun W，McConnell E，Pare JF，et al. Glutamate-dependent neuroglial calcium signaling differs between young and adult brain［J］. Science，2013，339（6116）：197-200.
[6]	Planas-Fontanez TM，Dreyfus CF，Saitta KS. Reactive astrocytes as therapeutic targets for brain degenerative diseases：roles played by metabotropic glutamate receptors［J］. Neurochem Res，2020，45（3）：541-550.
[7]	Sengmany K，Gregory KJ. Metabotropic glutamate receptor subtype 5：molecular pharmacology，allosteric modulation and stimulus bias［J］. Br J Pharmacol，2016，173（20）：3001-3017.
[8]	Eng AG，Kelver DA，Hedrick TP，et al. Transduction of group I mGluR-mediated synaptic plasticity by beta-arrestin2 signalling［J］. Nat Commun，2016，7：13571.
[9]	Luscher C，Huber KM. Group 1 mGluR-dependent synaptic long-term depression：mechanisms and implications for circuitry and disease［J］. Neuron，2010，65（4）：445-459.
[10]	Shiraishi-Yamaguchi Y，Furuichi T. The Homer family proteins［J］. Genome Biol ，2007，8（2）：206.
[11]	Holz A，Mulsch F，Schwarz MK，et al. Enhanced mGlu5 signaling in excitatory neurons promotes rapid antidepressant effects via AMPA receptor activation［J］. Neuron，2019，104（2）：338-352.
[12]	Ribeiro FM，Vieira LB，Pires RG，et al. Metabotropic glutamate receptors and neurodegenerative diseases［J］. Pharmacol Res，2017，115：179-191.
[13]	Bagni C，Zukin RS. A Synaptic perspective of fragile X syndrome and autism spectrum disorders［J］. Neuron，2019，101（6）：1070-1088.
[14]	Bruno V，Caraci F，Copani A，et al. The impact of metabotropic glutamate receptors into active neurodegenerative processes：a "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders［J］. Neuropharmacology，2017，115：180-192.
[15]	Pereira V，Goudet C. Emerging trends in pain modulation by metabotropic glutamate receptors［J］. Front Mol Neurosci，2018，11：464.
[16]	Hagerman RJ，Berry-Kravis E，Hazlett HC，et al. Fragile X syndrome［J］. Nat Rev Dis Primers，2017，3：17065.
[17]	Prieto M，Folci A，Martin S. Post-translational modifications of the fragile X mental retardation protein in neuronal function and dysfunction［J］. Mol Psychiatry，2020，25（8）：1688-1703.
[18]	Huber KM，Gallagher SM，Warren ST，et al. Altered synaptic plasticity in a mouse model of fragile X mental retardation［J］. Proc Natl Acad Sci U S A，2002，99（11）：7746-7750.
[19]	Gross C，Chang CW，Kelly SM，et al. Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome［J］. Cell Rep，2015，11（5）：727-736.
[20]	Aloisi E，Le Corf K，Dupuis J，et al. Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice［J］. Nat Commun，2017，8（1）：1103.
[21]	Guo W，Molinaro G，Collins KA，et al. Selective disruption of metabotropic glutamate receptor 5-Homer interactions mimics phenotypes of fragile X syndrome in mice［J］. J Neurosci，2016，36（7）：2131-2147.
[22]	Higashimori H，Morel L，Huth J，et al. Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse［J］. Hum Mol Genet，2013，22（10）：2041-2054.
[23]	Men YQ，Ye L，Risgaard RD，et al. Astroglial FMRP deficiency cell-autonomously up-regulates miR-128 and disrupts developmental astroglial mGluR5 signaling［J］. Proc Natl Acad Sci U S A，2020，117（40）：25092-25103.
[24]	Muller UC，Deller T，Korte M. Not just amyloid：physiological functions of the amyloid precursor protein family［J］. Nat Rev Neurosci，2017，18（5）：281-298.
[25]	Benarroch EE. Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease：emerging mechanisms［J］. Neurology，2018，91（3）：125-132.
[26]	Westmark CJ. Fragile X and APP：a decade in review，a vision for the future［J］. Mol Neurobiol，2019，56（6）：3904-3921.
[27]	Hu NW，Nicoll AJ，Zhang DN，et al. mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo［J］. Nat Commun，2014，5：3374.
[28]	Hamilton A，Vasefi M，Vander Tuin C，et al. Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model［J］. Cell Rep，2016，15（9）：1859-1865.
[29]	Abd-Elrahman KS，Hamilton A，Albaker A，et al. mGluR5 contribution to neuropathology in Alzheimer mice is disease stage-dependent［J］. ACS Pharmacol Transl Sci，2020，3（2）：334-344.
[30]	Doria JG，de Souza JM，Silva FR，et al. The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington''s disease［J］. J Neurochem，2018，147（2）：222-239.
[31]	Abd-Elrahman KS，Ferguson SSG. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington''s pathology in zQ175 mice［J］. Mol Brain，2019，12（1）：35.
[32]	Zhang Z，Zhang S，Fu P，et al. Roles of glutamate receptors in Parkinson''s disease［J］. Int J Mol Sci，2019，20（18）：4391.
[33]	Bonifacino T，Provenzano F，Gallia E，et al. In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1（G93A） mouse model of amyotrophic lateral sclerosis［J］. Neurobiol Dis，2019，129：79-92.
[34]	Murrough JW，Abdallah CG，Mathew SJ. Targeting glutamate signalling in depression：progress and prospects［J］. Nat Rev Drug Discov，2017，16（7）：472-486.
[35]	Wagner KV，Hartmann J，Labermaier C，et al. Homer1/mGluR5 activity moderates vulnerability to chronic social stress［J］. Neuropsychopharmacol，2015，40（5）：1222-1233.
[36]	Esterlis I，Holmes SE，Sharma P，et al. Metabotropic glutamatergic receptor 5 and stress disorders：knowledge gained from receptor imaging studies［J］. Biol Psychiatry，2018，84（2）：95-105.
[37]	Deschwanden A，Karolewicz B，Feyissa AM，et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by ［（11）C］ABP688 PET and postmortem study［J］. Am J Psychiatry，2011，168（7）：727-734.
[38]	Davis MT，Hillmer A，Holmes SE，et al. In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation［J］. Proc Natl Acad Sci U S A，2019，116（23）：11490-11495.
[39]	Shin S，Kwon O，Kang JI，et al. mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress［J］. Nat Neurosci，2015，18（7）：1017-1024.
[40]	Hefti K，Holst SC，Sovago J，et al. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep［J］. Biol Psychiatry，2013，73（2）：161-168.
[41]	Esterlis I，DellaGioia N，Pietrzak RH，et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response：an ［（11）C］ABP688 and PET imaging study in depression［J］. Mol Psychiatry，2018，23（4）：824-832.
[42]	Birnbaum R，Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia［J］. Nat Rev Neurosci，2017，18（12）：727-740.
[43]	Jorratt P，Hoschl C，Ovsepian SV. Endogenous antagonists of N-methyl-d-aspartate receptor in schizophrenia［J］. Alzheimers Dement，2021，17（5）：888-905.
[44]	Goff DC. D-cycloserine in schizophrenia：new strategies for improving clinical outcomes by enhancing plasticity［J］. Curr Neuropharmacol，2017，15（1）：21-34.
[45]	Geddes AE，Huang XF，Newell KA. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia［J］. Prog Neuropsychopharmacol Biol Psychiatry，2011，35（4）：896-904.
[46]	Matta JA，Ashby MC，Sanz-Clemente A，et al. mGluR5 and NMDA receptors drive the experience- and activity-dependent NMDA receptor NR2B to NR2A subunit switch［J］. Neuron，2011，70（2）：339-351.
[47]	Barnes SA，Pinto-Duarte A，Kappe A，et al. Disruption of mGluR5 in parvalbumin-positive interneurons induces core features of neurodevelopmental disorders［J］. Mol Psychiatry，2015，20（10）：1161-1172.
[48]	Wang HY，MacDonald ML，Borgmann-Winter KE，et al. mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia［J］. Mol Psychiatry，2020，25（4）：750-760.
[49]	Matosin N，Newell KA. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia［J］. Neurosci Biobehav Rev，2013，37（3）：256-268.
[50]	Ghoshal A，Moran SP，Dickerson JW，et al. Role of mGlu₅ receptors and inhibitory neurotransmission in M₁ dependent muscarinic LTD in the prefrontal cortex：implications in schizophrenia［J］. ACS Chem Neurosci，2017，8（10）：2254-2265.
[51]	Balu DT，Li Y，Takagi S，et al. An mGlu5-positive allosteric modulator rescues the neuroplasticity deficits in a genetic model of NMDA receptor hypofunction in schizophrenia［J］. Neuropsychopharmacology，2016，41（8）：2052-2061.
[52]	Dore AS，Okrasa K，Patel JC，et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain［J］. Nature，2014，511（7511）：557-562.
[53]	Hellyer S，Leach K，Gregory KJ. Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation［J］. Curr Opin Pharmacol，2017，32：49-55.
[54]	Pillai RL，Tipre DN. Metabotropic glutamate receptor 5-a promising target in drug development and neuroimaging［J］. Eur J Nucl Med Mol Imaging，2016，43（6）：1151-1170.
[55]	Xu Y，Li Z. Imaging metabotropic glutamate receptor system：application of positron emission tomography technology in drug development［J］. Med Res Rev，2019，39（5）：1892-1922.
[56]	Mecca AP，McDonald JW，Michalak HR，et al. PET imaging of mGluR5 in Alzheimer''s disease［J］. Alzheimers Res Ther，2020，12（1）：15.
[57]	Brasic JR，Nandi A，Russell DS，et al. Cerebral expression of metabotropic glutamate receptor subtype 5 in idiopathic autism spectrum disorder and fragile X syndrome：a pilot study［J］. Int J Mol Sci，2021，22（6）：2863.
[58]	Streffer J，Treyer V，Buck A，et al. Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by ［（11）C］-ABP688 PET imaging in healthy volunteers［J］. Neuroimage，2021，230：117785.
[59]	Berry-Kravis E，Hessl D，Coffey S，et al. A pilot open label，single dose trial of fenobam in adults with fragile X syndrome［J］. J Med Genet，2009，46（4）：266-271.

施引文献(3)

期刊类型引用(3)

1.	刘景坤，张斗胜，范慧红，廖海明. 首批L-甲硫氨酸亚砜国家药品对照品的研制. 药物分析杂志. 2024(08): 1373-1378 . 百度学术
2.	吴小飞，刘丹杏，王宏亮，白玉. 复方氨基酸注射液仿制药药学研究的相关考虑. 中国新药杂志. 2023(21): 2134-2139 . 百度学术
3.	郭雷，周长明，李辉，邵天舒. 复方氨基酸注射液(18AA-Ⅱ)有关物质2-磺基色氨酸的研究. 药物分析杂志. 2022(11): 2050-2055 . 百度学术